Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.
The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH).
The US FDA granted it Breakthrough Therapy designation for glioblastoma in Feb 2015 meaning that it might be able to get approval sooner if it is effective.
Clinical trials
Glioblastoma
The phase II ACT III study reported encouraging results in June 2015.
The ReACT clinical trial for glioblastoma reported encouraging results in 2015.
In March 2016 the phase III ACT IV trial was terminated because it did not increase overall survival.
References
- ^ Zussman; et al. (2015). "Outcomes of the ACT III Study: Rindopepimut (CDX-110) Therapy for Glioblastoma". Neurosurgery. 76 (6): N17. doi:10.1227/01.neu.0000465855.63458.0c. PMID 25985004.
- ^ Celldex Vaccine Rindopepimut Cuts Death Risk From Brain Cancer, Study Shows. WSJ Nov 2015
- "FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive Glioblastoma. Feb 2015". Archived from the original on 2016-05-05. Retrieved 2016-04-18.
- rindopepimut definition
- Khleif, Samir N.; Rixe, Olivier; Skeel, Roland (2016). Skeel's Handbook of Cancer Therapy. Lippincott Williams & Wilkins. ISBN 9781496353399.
- Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)
- "Rindopepimut Misses OS Endpoint in Phase III Glioblastoma Trial. March 2016". Archived from the original on 2016-05-05. Retrieved 2016-04-18.
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |